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Anaplastic Lymphoma Kinase Gene Rearrangements in
Non-small Cell Lung Cancer are Associated with Prolonged
Progression-Free Survival on Pemetrexed
D. Ross Camidge, MD, PhD,* Scott A. Kono, DO,* Xian Lu, PhD,† Sonia Okuyama, MD,*
Anna E. Baro´n, PhD,† Ana B. Oton, MD,* Angela M. Davies, MD,* Marileila Varella-Garcia, PhD,*‡
Wilbur Franklin, MD,‡ and Robert C. Doebele, MD, PhD*
Hypothesis: To explore whether the progression-free survival (PFS)
with pemetrexed differs between anaplastic lymphoma kinase
(ALK)-positive and other major molecular subtypes of non-small
cell lung cancer.
Methods: In an ALK-enriched population, patients with metastatic
non-small cell lung cancer were screened by ALK fluorescence in
situ hybridization and for epidermal growth factor receptor (EGFR)
and KRAS mutations. Triple-tested, pemetrexed-treated patients
(monotherapy or combination therapy) were identified and PFS with
pemetrexed captured retrospectively.
Results: Eighty-nine eligible cases were identified (19 ALK fluo-
rescence in situ hybridization positive, 12 EGFR mutant, 21 KRAS
mutant, and 37 triple negatives). Eighty-three cases (93%) were
adenocarcinomas, two were adenosquamous, one squamous, and
three had large cell histology. None of the ALK-positive patients
had received crizotinib before pemetrexed. Pemetrexed was first-line
therapy in 48% (72% as platinum-based combinations). Median PFS
(95% confidence interval) data were EGFR mutant (5.5 months;
1–9), KRAS mutant (7 months; 1.5–10), ALK positive (9 months;
3–12), and triple negative (4 months; 3–5). In a multivariate analysis
adjusting for line of therapy, mono- versus platinum and nonplati-
num combination therapy, age, sex, histology, and smoking status,
the only variable associated with prolonged PFS on pemetrexed was
ALK (hazard ratio  0.36 [95% confidence interval: 0.17–0.73],
p  0.0051).
Conclusions: In this exploratory analysis, ALK-positive patients
have a significantly longer PFS on pemetrexed compared with
triple-negative patients, whereas EGFR or KRAS mutant patients do
not. This information should be considered when sizing randomized
studies in ALK-positive patients that involve pemetrexed. Pem-
etrexed should also be prioritized as a cytotoxic to explore further in
patients with known ALK-positive disease.
Key Words: Anaplastic lymphoma kinase, Non-small cell lung
cancer, Epidermal growth factor receptor, KRAS, Pemetrexed.
(J Thorac Oncol. 2011;6: 774–780)
The identification of specific molecular abnormalities insubgroups of non-small cell lung cancer (NSCLC) offers
the potential for developing targeted therapies in defined
molecular subpopulations of this disease. The development
plans for targeted therapies in such populations often involve
direct comparisons to standard cytotoxics.1,2 With the recent
discovery of anaplastic lymphoma kinase (ALK) gene rear-
rangements in NSCLC associated with marked sensitivity to
crizotinib, a small molecule inhibitor of ALK, clinical devel-
opment plans for this agent include a randomized second-line
study in advanced ALK-positive NSCLC compared with
either pemetrexed or docetaxel.3–5 To size such studies,
outcomes in the chemotherapy control arm in molecularly
selected populations are often assumed to be comparable with
that in historical unselected series.6,7 Nevertheless, within
some molecularly enriched studies, a differential effect of
carboplatin-paclitaxel on epidermal growth factor receptor
(EGFR) mutant and wild-type tumors has already been noted
(objective response rates of 47% versus 23%, respectively),
confirming the possibility that different molecular subtypes of
lung cancer may behave differently with standard treatments,
as well as with specific targeted therapies.1
Since 2008, the University of Colorado has conducted
routine molecular screening for EGFR and KRAS mutations
and, most recently, ALK gene rearrangements, on all patients
with NSCLC with adequate tissue.8 These data are generated
by the onsite Clinical Laboratory Improvement Amendments-
certified Colorado Molecular Correlates (CMOCO) Labora-
tory. After the clinical observation that several patients with
protracted disease control within an in-house pemetrexed/
multitargeted kinase inhibitor combination study turned out
to harbor ALK gene rearrangements, we chose to formally
assess differential benefit from pemetrexed across patients
with stage IV NSCLC with ALK and other molecular abnor-
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malities. ALK gene rearrangements are rarer than EGFR and
KRAS mutations in unselected series, but due to the Univer-
sity of Colorado adopting an initial screening enrichment
policy, as well as offering ALK testing to outside institutions
and access to crizotinib within clinical trials, sufficient ALK-
positive cases have been concentrated at the University to
make intermolecular group comparisons that include ALK
gene rearrangements feasible.9 In this study, we demonstrate
that in a multivariate analysis, adjusting for line of therapy,
mono- versus platinum and nonplatinum combination ther-
apy, age, sex, histology, and smoking status, the progression-
free survival (PFS) on pemetrexed in patients with metastatic
NSCLC is significantly longer among those harboring ALK
gene rearrangements but not among those with either EGFR
or KRAS mutant patients, compared with a control triple-
negative group.
PATIENTS AND METHODS
Patients
The University of Colorado Thoracic Oncology Pro-
gram began routine EGFR and KRAS mutation testing in
2008. Shortly after this, screening of tumor biopsies from
patients with NSCLC for ALK gene rearrangements by fluo-
rescence in situ hybridization (FISH) using the Abbott break-
apart probes began with the goal of identifying patients for
entry into defined molecular cohorts within the phase I study
of crizotinib (PF-02341066).5,8,9 Because of a growing
awareness of the features most associated with ALK positiv-
ity, our initial ALK screening strategies deliberately enriched
for those likely to be ALK positive, including not testing
those who were previously proven EGFR or KRAS mutant.9
Later, however, in a desire to capture all ALK-positive cases,
we adopted a different policy, screening all NSCLC cases
with available tissue.10
Mutational analyses and ALK FISH testing were con-
ducted as described previously.10,11 Briefly, EGFR exons 19,
20, and 21 and KRAS exon 2 were amplified and sequenced
using an ABI model 3730 capillary gel sequencer. Mutations
were identified by visual inspection of the resulting chro-
matograms and automated scanning using Mutation Surveyor
v3.24. On FISH testing, the occurrence of an ALK gene
rearrangement (ALK FISH positive) was concluded if more
than 15% of tumor cells showed split red and green signals
and/or single red (residual 3) signals, otherwise the specimen
was classified as ALK FISH negative.10 An institutional
review board-approved protocol permits clinical correlates to
be made on all in-house patients in whom molecular analyses
have been conducted within the CMOCO laboratory. All
patients with NSCLC with stage IV cancer (Tumor, Nodes,
Metastases, 7th edition) tested within CMOCO laboratory
from June 2008 were reviewed for (a) full triple testing
(EGFR and KRAS mutation status and ALK gene rearrange-
ments) and (b) treatment of their advanced disease with either
monotherapy or combination therapy with pemetrexed. As
ALK FISH analysis was the last of the three tests to be
introduced into the CMOCO panel, those patients tested for
ALK gene rearrangements were identified first and then re-
viewed in detail for full triple test results. Treatment with
pemetrexed as standard of care or within a clinical trial was
permissible. No minimum exposure to pemetrexed was man-
dated.
Data were collected by retrospective scan and chart
review for each patient, capturing NSCLC histology, age,
sex, smoking status, whether the pemetrexed was given as
monotherapy or combination therapy (with platinum or non-
platinum agents), and the line of therapy for metastatic
disease in which the pemetrexed was given (not including
adjuvant therapy, neoadjuvant therapy, chemoradiation, or
monotherapy with small molecule inhibitors as lines of ther-
apy for this calculation). Patients who received initial com-
bination pemetrexed, then continued maintenance pem-
etrexed monotherapy were included in the “combination”
group. Patients were classified as either “never/light smok-
ers” if they smoked less than 10 pack years or as “smokers”
if they smoked10 pack years in their lifetime. Patients were
excluded if clinical information was incomplete. The PFS on
pemetrexed was documented for each patient, rounded to the
nearest half month, and taken as the time from the first dose
of pemetrexed until first documented clinical or radiographic
progression, escalation or change in therapy (“systemic pro-
gression”), or death from any cause. Patients who were alive
but had not progressed at the time of the analysis (October 14,
2010) were noted and censored within the analyses. Best
objective responses per RECIST version 1.1 were assessed on
patients with measurable disease.
Statistical Analyses
Descriptive analyses were performed on four molecu-
larly defined groups: ALK FISH positive, EGFR mutant,
KRASmutant, and triple negative and associated clinical data.
Kaplan-Meier (KM) curves were generated for PFS within
each group. Cox proportional hazards regression was used to
obtain unadjusted and adjusted hazard ratio (HR) estimates
for each of the ALK FISH positive (), EGFR mutant, and
KRAS mutant group versus the triple-negative group. In a
multivariate analysis, the following potential confounding
variables were included: line of therapy, mono- versus plat-
inum and nonplatinum combination therapy, age, sex, histol-
ogy, and smoking status. Diagnostics for the functional form
of line of therapy and age at diagnosis suggested that both
line of therapy and age could be included as continuous
variables.12 Reference groups in the multivariate analysis
were as follows: smoking status, nonsmoker; histology, ade-
nocarcinoma; treatment type, monotherapy; sex, male; and
mutation, triple negative. All tests and confidence intervals
(CIs) were two sided with conclusions based on a significance
level of 0.05. Statistical analyses were performed using SAS/
BASE and SAS/STAT software, Version 9.2 of the SAS
System for Windows (SAS Institute Inc., Cary, NC).
RESULTS
Triple-Tested Patients Receiving Pemetrexed
Of the 124 patients tested for ALK gene rearrangements
within the CMOCO laboratory from October 2008 up to May
2010, 117 were triple tested. The following patients were
excluded: five because no associated clinical data were avail-
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able, 20 because they had not received pemetrexed, two
because the pemetrexed was given concurrently with radia-
tion, and one because, despite prolonged pemetrexed use and
multiple biopsies, no histologically confirmed disease had
been documented. The demographics and treatment details of
the final 89 triple-tested, pemetrexed-treated patients with
stage IV NSCLC used in the PFS analyses are listed in Table
1. Primary PFS events were as follows: systemic progression
(78), death before progression (4), and alive without progres-
sion (seven, one of whom had all sites of disease resected and
follow-up was taken to date of surgery only). Five patients
(one EGFR mutant, one ALK positive, and three triple
negative) continued to receive pemetrexed after local treat-
ment of central nervous system-only progression. Rational-
izing that central nervous system-only progression reflected
primarily a failure of central nervous system penetration
rather than true drug resistance, the time to systemic progres-
sion was captured as the primary event in these individuals.
Almost all systemic progression events occurred while still
on pemetrexed, but a small number of patients discontinued
pemetrexed before progression or death due to either toxicity
(eight cases) or administration of a predefined fixed number
of cycles (five cases). Eighty-three cases were adenocarcino-
mas, two adenosquamous, one squamous, and three had large
cell histology. Nineteen were ALK FISH positive, 12 and 21
were EGFR and KRAS mutants, respectively, and 37 were
triple negative. No cases had more than one positive result.
None of the ALK-positive patients had received crizotinib
before pemetrexed. Pemetrexed was given in the first-line
setting in 43 patients (48% of cases), 31 of whom received it
as part of a platinum-containing regimen. Overall, pem-
etrexed was given as monotherapy in 38 cases, as a platinum-
based combination in 36 cases, and as a nonplatinum-based
combination, predominantly with a targeted therapy, in 15
cases (eight with bevacizumab, three with sunitinib, and one
each with bortezomib, gemcitabine, erlotinib, or cetuximab).
PFS Data
A waterfall plot of the PFS for patients within each of
the four cohorts is shown in Figure 1. KM curves of PFS for
the four cohorts are shown in Figure 2. The median PFS and
95% CI in months from the KM curves were EGFR mutant
(5.5 months; 1–9), KRAS mutant (7 months; 1.5–10), ALK
positive (9 months; 3–12), and triple negative (4 months;
3–5). The median, minimum, and maximum ranges of fol-
low-up/duration of therapy were EGFR mutant (5.5 months;
0.5–9), KRAS mutant (7 months; 0.5–16), ALK positive (9
months; 1.5–21), and triple negative (4 months; 1–12.5). HR
and 95% CIs looking at the univariate relationship between
PFS and molecular subtype compared with the triple-negative
cohort were EGFR mutant (HR: 1.04 [0.52–2.05], p 
0.9185), KRAS mutant (HR: 0.58 [0.32–1.07], p  0.0818),
and ALK FISH positive (HR: 0.44 [0.24–0.81], p  0.0082).
Investigation of the proportional hazards assumption was
TABLE 1. Baseline Patient Characteristics (n  89)
Variables, No. (%)
ALK Positive
(n  19)
EGFR Mutant
(n  12)
KRAS Mutant
(n  21)
Triple Negative
(n  37)
Sex
Male 9 (47%) 3 (25%) 6 (29%) 13 (35%)
Female 10 (53%) 9 (75%) 15 (71%) 24 (65%)
Smoking status
Never/light smoker 16 (84%) 8 (67%) 3 (14%) 16 (43%)
Smoker 3 (16%) 4 (33%) 18 (86%) 21 (57%)
Line of therapy
First 12 (63%) 4 (33%) 13 (62%) 14 (38%)
Second 6 (32%) 7 (58%) 7 (33%) 16 (43%)
Third 0 1 (8%) 1 (5%) 6 (16%)
Fourth 1 (5%) 0 0 1 (3%)
Histology
Adenocarcinoma 18 (95%) 12 (100%) 19 (90%) 34 (92%)
Squamous cell 0 0 0 1 (3%)
Adenosquamous 0 0 0 2 (5%)
Large cell 1 (5%) 0 2 (10%) 0
Median age (yr) 46 60 58 59
Treatment type
Pemetrexed monotherapy 6 (32%) 8 (66%) 7 (33%) 17 (46%)
Pemetrexed combination therapy 13 (68%) 4 (33%) 14 (67%) 20 (54%)
Platinum combination 10 (77%) 3 (75%) 11 (79%) 12 (60%)
Nonplatinum combination 3 (23%)a 1 (25%)b 3 (21%)c 8 (40%)d
a Bevacizumab (n  1) and sunitinib (n  2).
b Erlotinib (n  1).
c Bortezomib (n  1), sunitinib (n  1), and cetuximab (n  1).
d Bevacizumab (n  6), sunitinib (n  1), and gemcitabine (n  1).
ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor.
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performed for ALK, EGFR mutant, and KRAS mutant
versus the triple-negative group.12 Evidence for nonconstant
HRs was only present for the EGFR mutant group whose
hazard function crossed the hazard function for the triple-
negative group, resulting in a nonsignificant HR. After ad-
justing for line of therapy, age at diagnosis, sex, smoking
status, platinum combination versus nonplatinum combina-
tion versus monotherapy, and histology, only one statistically
significant variable, ALK positivity, was associated with
prolonged PFS on pemetrexed (Table 2). The HR for ALK
positivity within the multivariate analysis was 0.36 (0.17–
0.73), p  0.0051 (Table 2). With respect to the other
variables in the multivariate model, pemetrexed delivered as
a nonplatinum combination was also associated with pro-
longed PFS, but the statistical significance was marginal (p
0.0494). Two variables (line of therapy [p  0.0221] and
large cell histology [p  0.0001]) were statistically signifi-
cantly associated with worsened PFS on pemetrexed (Table 2).
Response data per RECIST are listed in Table 3.
The majority of our patients were still alive at the time
of analysis (data not shown), and therefore, no estimates of
median overall survival were made.
DISCUSSION
Pemetrexed was initially licensed by the United States
Food and Drug Administration for all NSCLC histologies but
after a series of histological subgroup analyses, subsequently
licensed only for the treatment of nonsquamous NSCLC.13–16
Given its relatively low toxicity, unlike many other cytotoxic
therapies, treatment with pemetrexed until progression is
becoming common practice in the general oncology commu-
nity and within ongoing clinical trials of this agent.7,17 This
may be either in the monotherapy setting or as continuation of
the pemetrexed alone from an initial first-line platinum-
pemetrexed doublet. The median PFS in patients with nons-
quamous NSCLC (not otherwise specified) from the registra-
tion studies of a first-line platinum-pemetrexed doublet and
second-line pemetrexed monotherapy were 5.26 and 3.1
months, respectively.15
In this study, we report the results of an exploratory
analysis looking at the PFS on pemetrexed by molecular
subtype of advanced NSCLC. To maximize the size of the
dataset for statistical comparisons among these relatively rare
subgroups, we explored a composite population of pem-
etrexed-treated patients looking across lines of therapy in
both the monotherapy and combination settings. Inevitably,
because of the nature of the available information, the data in
this retrospective study are not as robust as within a prospec-
tively collected dataset. We do not, for example, have infor-
mation on baseline performance status. In addition, all pa-
tients within this single-center observational study may not
have had the same frequency of follow-up, which could
potentially affect PFS estimates. Nevertheless, the entry cri-
teria and data collection methodologies were uniformly ap-
plied to the study population, so relative differences between
the cohorts, particularly when adjusted by other potential PFS
modifying factors within the multivariate analysis, are still
most likely to reflect differences in the underlying biology.
There was a notable excess of never/light smokers among the
EGFR mutant and ALK gene rearranged cohorts, and a
notable excess of smokers among the KRAS mutant cohort,
consistent with the known risk factors associated with these
molecular subtypes (Table 1).4,18,19 Similarly, the median age
at diagnosis was lowest among the ALK-positive cohort
consistent with previous reports.4,20 As expected, the majority
of patients treated with pemetrexed had nonsquamous
NSCLC, predominantly adenocarcinoma. Because of this
histologic association and the fact that we initially adopted an
ALK screening policy that focused primarily on those with-
out known EGFR or KRAS mutations, the incidence of ALK
gene rearrangements in this triple-tested, pemetrexed-treated
series was higher (21%) than in most previously reported
unselected series.4,9,20 Overall, patients with ALK gene rear-
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FIGURE 1. Waterfall plot of the progression-free survival
(PFS) for patients within the anaplastic lymphoma kinase
(ALK) fluorescence in situ hybridization (FISH) positive, epi-
dermal growth factor receptor (EGFR) mutant, KRAS mutant,
and triple-negative cohorts. The median PFS in months
(from the Kaplan-Meier analysis) and their 95% confidence
intervals (CIs) are shown in the insert boxes. Patients still on
treatment but censored for progression at the time of analy-
sis are shown as white bars, and patients who experienced a
treatment failure event during the observation period of the
study are shown as black bars.
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rangements had a longer median PFS on pemetrexed than
KRAS mutant, EGFR mutant, or triple-negative patients (9
months compared with 7, 5.5, and 4 months, respectively)
(Figures 1 and 2). Nevertheless, in this retrospective analysis,
multiple other confounding factors may contribute to this.
Therefore, it is important to note that in the multivariate
analysis adjusting for line of therapy, mono- versus platinum
and nonplatinum combination therapy, age, sex, histology
and smoking status, the only statistically significant variable
associated with prolonged PFS on pemetrexed was ALK
(HR  0.36 [95% CI: 0.17–0.73], p  0.0051) (Table 2).
Although not statistically significant in terms of HR, the
KRAS mutant population is also worthy of mention as the
waterfall plot in Figure 1 suggests two relatively distinct
subgroups may exist within this cohort (approximately 50:50,
rapid progressors versus longer PFS outcomes with pem-
etrexed), the basis of which is currently unknown.
When interpreting our findings related to ALK, several
caveats must be considered in the absence of data from a
randomized study. Although ALK gene rearrangements may
be predictive of pemetrexed benefit specifically, they may also
be predictive of general chemotherapy sensitivity or may be
associated with a good prognosis. As the majority of our
ALK-positive patients received their pemetrexed in the first-
line setting before receiving crizotinib, we have few cases in
which to compare outcomes with other treatments. In a series
by Shaw et al.,20 the PFS of ALK-positive patients with
platinum-based first-line combination chemotherapy, where
the partner cytotoxic was not specified, appeared no different
from EGFR mutant or double-negative (ALK and EGFR wild
type) patients. In contrast, in a different study among patients
specifically treated with cisplatinum and pemetrexed as the
first-line combination, the median time to progression was 6.2
months among 32 ALK-negative patients but 9 months
among the eight ALK-positive patients analyzed.21 A differ-
ence remarkably similar to our own results. Although this
ALK + Censored ALK +
EGFR Mutant Censored EGFR Mutant
KRAS Mutant Censored KRAS Mutant
Triple Negative Censored Triple Negative
HR (95% CI), compared to triple negative cohort:
EGFR mutant HR 1.04 (0.52 - 2.05), p = 0.9185
KRAS mutant HR 0.58 (0.32 - 1.07), p = 0.0818
ALK positive HR 0.44 (0.24 - 0.81), p = 0.0082
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FIGURE 2. Kaplan-Meier curves of
progression-free survival (PFS) for
the four molecular subtype cohorts.
Hazard ratios (HRs) and their 95%
confidence intervals (CIs) looking at
the univariate relationship between
PFS and molecular subtype, com-
pared with the triple-negative cohort
are shown within the insert box.
TABLE 2. Multivariate Analysis
Parameters
Hazard
Ratio
95% Confidence
Intervals p (2)
Molecular status (compared with
triple negative)
ALK 0.36 0.17–0.73 0.0051a
EGFR mutant 1 0.49–2.04 0.9983
KRAS mutant 0.55 0.28–1.1 0.0952
Line of therapy 1.57 1.07–2.31 0.0221a
Age at diagnosis 1 0.98–1.02 0.7918
Smoking status (compared with
nonsmokers)
1.06 0.63–1.76 0.8368
Histology (compared with
adenocarcinoma)
Adenosquamous 0.46 0.1–2.06 0.3093
Large cell 15.1 3.8–59.93 0.0001a
Squamous 6.07 0.73–50.66 0.0958
Type of therapy (compared with
pemetrexed monotherapy)
Nonplatinum combination 0.5 0.25–1.0 0.0494a
Platinum combination 0.85 0.44–1.63 0.6182
Sex 1.59 0.96–2.64 0.0746
a p values 0.05.
ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor.
Camidge et al. Journal of Thoracic Oncology • Volume 6, Number 4, April 2011
Copyright © 2011 by the International Association for the Study of Lung Cancer778
does not exclude increased responsiveness to other cytotoxic
therapies, these data do suggest that the prolonged PFS on
pemetrexed we observe at least represents a true differential
effect of pemetrexed between molecular subtypes of NSCLC.
With respect to prognosis, in one recent series, ALK
FISH-positive patients, who had not been treated with crizo-
tinib, seemed to have an overall survival no different from
EGFR mutant and double-negative (ALK and EGFR wild
type) patients (p  0.774).22 In addition, within our series,
among those with available data on measurable disease, the
best response assessments per RECIST demonstrate higher
objective response rates (across first-line platinum-pem-
etrexed combinations, pemetrexed monotherapy, and all cat-
egories of treatment combined) among the ALK patients
than in almost any other group (Table 3). Although our
response datasets are too small to consider statistical com-
parisons, they are consistent with the prolonged PFS in
ALK lung cancer representing genuine benefit from the
pemetrexed and not simply a reflection of slow-growing
disease.
The underlying biology to explain why ALK-positive
patients should derive greater clinical benefit from pemetrexed
than other molecularly defined subtypes of NSCLC is unclear;
however, it is possible to generate a hypothesis based on the
drug’s mechanisms of action. Pemetrexed is an antifolate with
activity against three major enzymes involved in purine and
pyrimidine synthesis, namely thymidylate synthase, dihydrofo-
late reductase (DHFR), and glycinamide ribonucleotide formyl-
transferase.13 Pemetrexed may also affect another lesser known
folate pathway enzyme, ATIC (5-aminoimidazole-4-carboxam-
ide ribonucleotide formyltransferase/inosine monophosphate cy-
clohydrolase), a bifunctional enzyme that catalyzes the last two
steps of de novo purine biosynthesis. This effect may be either
direct or indirect by DHFR, as DHFR generates tetrahydrofolate,
and ATIC is dependent on tetrahydrofolate as a cofactor.23,24 A
narrower spectrum antifolate, praletrexate, which also has
activity against both DHFR and ATIC, has demonstrated
striking activity in a small group of ALK-positive anaplastic
large T-cell lymphomas, where the duration of response
exceeded 22 months.23,25 Anaplastic large T-cell lymphoma
represents another ALK fusion protein-driven disease, in
which nucleophosmin is the most common 5 fusion partner
for the kinase.26 Recently, it has been shown that the enzy-
matic activity of ATIC is increased by ALK-mediated phos-
phorylation.27 Taken together, it is possible to hypothesize
that ALK increases ATIC activity, which, either directly or
indirectly, then makes ALK-positive malignancies more sus-
ceptible to antifolate chemotherapy.
The discovery of prolonged PFS with pemetrexed in ALK
FISH-positive NSCLC has a number of significant ramifica-
tions. First, regardless of its basis, this result illustrates how
designing randomized studies in a selected population based on
chemotherapy outcomes in unselected populations may intro-
duce sizing errors. For the ongoing randomized study of crizo-
tinib, the comparator arm is either pemetrexed or docetaxel
(www.clinicaltrials.gov identifier: NCT00932893). The differ-
ential effect of docetaxel in different molecular subtypes of
NSCLC is still unknown (insufficient numbers of our patients
had received docetaxel to make this analysis informative at
present). Nevertheless, ALK-positive patients randomized to
pemetrexed within this study, by extension from the data shown
here, are likely to have a much longer median PFS than that seen
in the unselected or nonsquamous historical series used for the
trial’s initial sample size calculation.7,15
Second, assuming that the prolonged PFS from pem-
etrexed in ALK-positive patients does reflect true clinical benefit
as opposed to being a surrogate for a generally good prognostic
group, pemetrexed, in addition to crizotinib, should be priori-
TABLE 3. Best Response Data per RECIST v. 1.1 (Measurable Disease)
Overall
ALK Positive
(n  19)
EGFR Mutant
(n  10)
KRAS Mutant
(n  19)
Triple Negative
(n  36)
Complete response 0 0 1 (5%) 0
Partial response 8 (42%) 3 (30%) 6 (32%) 5 (14%)
Stable disease 10 (53%) 4 (40%) 4 (21%) 20 (56%)
Progressive disease 1 (5%) 3 (30%) 8 (42%) 11 (31%)
First-Line Platinum-
Pemetrexed Combination
ALK Positive
(n  10)
EGFR Mutant
(n  3)
KRAS Mutant
(n  10)
Triple Negative
(n  8)
Complete response 0 0 1 (10%) 0
Partial response 7 (70%) 3 (100%) 5 (50%) 1 (13%)
Stable disease 3 (30%) 0 2 (20%) 3 (38%)
Progressive disease 0 0 2 (20%) 4 (50%)
Pemetrexed Monotherapy
(Any Line)
ALK Positive
(n  6)
EGFR Mutant
(n  7)
KRAS Mutant
(n  5)
Triple Negative
(n  16)
Complete response 0 0 0 0
Partial response 1 (17%) 0 0 2 (12%)
Stable disease 4 (67%) 4 (57%) 1 (20%) 9 (56%)
Progressive disease 1 (17%) 3 (43%) 4 (80%) 5 (31%)
ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor.
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tized as one of the treatments of choice to explore further for this
molecular subtype of NSCLC.5 Whether prior crizotinib could
affect outcomes from pemetrexed remains unknown, as all the
patients described in this study had not received crizotinib before
pemetrexed exposure. Pemetrexed outcomes in ALK-positive
patients post-ALK inhibitor therapy should be captured to ad-
dress this. In addition, the potential for other antifolates to show
benefit in this defined subtype of NSCLC should be explored in
the future.
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